Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,509.01 +33.92 (+0.62%) Dow
39,331.85 +162.33 (+0.41%) Nasdaq
18,028.76 +149.46 (+0.84%) Bitcoin USD
60,553.82 -2,026.18 (-3.24%) CMC Crypto 200
1,305.57 -29.35 (-2.20%)
YMAB Nov 2024 25.000 call
- GlobeNewswire
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. “Y-mA
- Simply Wall St.
With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest
Key Insights Significantly high institutional ownership implies Y-mAbs Therapeutics' stock price is sensitive to their...
- GlobeNewswire
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that preclinical GD2-SADA data will be presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting taking place June 8 – 11, 2024, in Toronto, Can
